Cardlytics (CDLX) Tops Q1 EPS by 23c, Beats on Revenue; Offers Q2 Revenue Guidance

Cardlytics (NASDAQ: CDLX) reported Q1 EPS of ($0.21), $0.23 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $61.9 million versus the consensus estimate of $61.26 million.

GUIDANCE:

Cardlytics sees Q2 2025 revenue of $61-67 million, versus the consensus of $64.4 million.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.

You May Also Be Interested In

• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand
• RBC Capital Starts Opus Genetics (IRD) at Outperform
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight